The low incidence of extrapyramidal side effects associated with the atypical antipsychotic iloperidone may be linked to its unique binding profile of high affinity antagonism of both a1 adrenergic receptors and serotonin 2A receptors.
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ISSUE:
The low incidence of extrapyramidal side effects associated with the atypical antipsychotic iloperidone may be linked to its unique binding profile of high affinity antagonism of both a1 adrenergic receptors and serotonin 2A receptors.
Take-Home Points 3. These same pyramidal neurons are also regulated by a1 adrenergic receptors, and when blocked, a1 adrenergic antagonism also hypothetically causes additional downstream release of striatal dopamine.
4. Iloperidone has a unique combination of potent a1 adrenergic antagonism plus 5HT 2A antagonism, which may explain its very low association with EPS.
All antipsychotics block D 2 dopamine receptors and 5HT 2A serotonin receptors. 1 Actions at other receptors differentiate the pharmacology of one atypical antipsychotic from another. 1 In the case of iloperidone, the pharmacologic action that distinguishes it most from other atypical antipsychotics is its potent antagonism of a1 adrenergic receptors; in fact, this property is the most potent of all the pharmacologic actions of iloperidone. [1] [2] [3] Perhaps the most distinguishing clinical property of iloperidone is its low placebo level of inducing extrapyramidal side effects (EPS). 4, 5 Examining the regulation of dopamine release by pyramidal neurons can provide a hypothetical link between potent a1 adrenergic antagonism, 5HT 2A antagonism, and low EPS. (Figure 1, box 2) . Release of dopamine from neurons in the striatum is thus inhibited.
5HT 2A antagonism cuts the brake cable 5HT 2A antagonism of cortical pyramidal neurons by an atypical antipsychotic interferes with serotonin by applying its braking action to dopamine release via 5HT 2A receptors (Figure 2, box 1) . Thus, 5HT 2A antagonism in the cortex hypothetically stimulates downstream dopamine release in the striatum. It does this by reducing glutamate release in the brainstem, which in turn fails to trigger the release of inhibitory GABA at dopamine neurons there ( Figure 2, box 2) . Release of dopamine from neurons downstream in the striatum is thus disinhibited, which should theoretically mitigate EPS.
5HT 2A receptor antagonism theoretically makes an antipsychotic atypical: low EPS
Normally, serotonin reduces dopamine release from the striatum by actions of serotonin at the various 5HT 2A receptors discussed above (Figure 1) (Figure 2 ). The result of this increased dopamine release is that dopamine competes with drug at D 2 receptors in the striatum, and reduces the D 2 receptor binding there below 80% to more like 60%, which is enough to reduce extrapyramidal symptoms. 1 This is the hypothesis that is most frequently linked to the explanation for the mechanism of the most important distinguishing clinical properties of atypical antipsychotics, namely low EPS with comparable antipsychotic actions.
a1 Adrenergic Antagonism
Due to the presence of stimulatory a1 adrenergic receptors on the same glutamate neurons that contain stimulatory 5HT 2A receptors, 7 it is possible that blockade of a1 adrenergic receptors may have the same downstream effects as blockade of 5HT 2A receptors, and that this could hypothetically contribute to the reduction of EPS seen with agents having potent a1 adrenergic antagonist actions. This is suggested by the fact that preclinical studies show that norepinephrine acting at postsynaptic a1 receptors (Figure 3 ) can stimulate the same pyramidal neurons in the prefrontal cortex that serotonin acting at postsynaptic 5HT 2A receptors stimulate (see Figure 1) . 7 By analogy, therefore, if blocking 5HT 2A receptors reduces EPS by the downstream actions of such neurons (Figure 2) , it may be possible that blocking a1 receptors on these same neurons would also reduce EPS (Figure 4 ). a1 adrenergic receptors are co-localized with 5HT 2A receptors on pyramidal neurons in the prefrontal cortex 8 and regulate several downstream neurotransmitters including dopamine. [9] [10] [11] [12] [13] [14] a1 adrenergic receptors are brakes on dopamine release in the striatum a1 adrenergic receptor-mediated stimulation of cortical pyramidal neurons by norepinephrine ( Figure 3 ) hypothetically blocks downstream dopamine release in the striatum. [7] [8] [9] [10] [11] [12] [13] [14] [15] ) It does this hypothetically via stimulation of glutamate release in the brainstem that triggers release of inhibitory GABA there (Figure 3) analogous to how 5HT does this same action (Figure 1) . Release of dopamine from neurons in the striatum is thus inhibited.
a1 adrenergic antagonism cuts the brake cable a1 adrenergic antagonism of cortical pyramidal neurons by an atypical antipsychotic interferes with norepinephrine by applying its braking action to dopamine release via a1 adrenergic receptors ( Figure  4, box 1) . Thus, a1 adrenergic antagonism in the cortex hypothetically would stimulate downstream dopamine release in the striatum. It would do this by reducing glutamate release in the brainstem, which in turn fails to trigger the release of inhibitory GABA at dopamine neurons there ( Figure 4, box 2) . Release of dopamine from neurons downstream in the striatum is thus disinhibited, which should theoretically mitigate EPS, analogous to how 5HT is thought to have this same action ( Figure 2, box 2) .
Iloperidone
Iloperidone is one of the newer atypical antipsychotics with 5HT 2A /D 2 antagonist properties. [1] [2] [3] [4] [5] [6] One of its most distinguishing clinical properties is a very low level of EPS associated with its use. [1] [2] [3] [4] [5] Its most distinguishing pharmacological property is its potent a1 antagonism. [1] [2] [3] 6 Although it is unknown why iloperidone, like quetiapine and clozapine, has a low incidence of EPS, it may be in part due to the fact that all 3 of these agents have high affinity for a1 receptors as well as for 5HT 2A receptors. 1, 2, 15 Theoretically, low EPS has been linked both to high affinity for 5HT 2A receptors (Figures 1-3 ) and to high affinity for a1 adrenergic receptors. 1, 2, 15 One outlier to this theory is risperidone, which has relatively high a1 receptor binding, but nevertheless has higher rates of EPS.
Summary
In summary, the combination of a potent blockade of both 5HT 2A and a1 receptors is a novel hypothesis for the low EPS of iloperidone, clozapine, and quetiapine. The very low, placebo-level incidence of EPS associated with iloperidone may thus be explained not only by its 5HT 2A antagonist properties, which are shared with every other member of the atypical antipsychotic class, but also by combining this action with the most potent a1 antagonist action of any atypical antipsychotic.
